Influencing Care in Acute Myocardial Infarction: A Randomized Trial Comparing 2 Types of Intervention

The purpose of this study was to evaluate performance feedback delivered by on-site presentations compared to mailed feedback on improving acute myocardial infarction (AMI) care. We used a randomized trial including 18 hospitals nested within the Cooperative Cardiovascular Project. Patients comprised AMI Medicare patients admitted before (n = 929, 1994 and 1995) and after intervention (n = 438, 1996). Control hospitals received written feedback by mail. The experimental intervention group received a presentation led by a cardiologist and a quality improvement specialist. We assessed the proportion of patients receiving appropriate AMI care before and after the intervention. Both univariate and multivariate analyses demonstrated no effect of the intervention in increasing the proportion of patients who received reperfusion, aspirin, beta-blockers, or angiotensin-converting enzyme in- hibitors. On-site feedback presentations were not associated with a larger improvement in AMI care compared to the mailed feedback. Other interventions, such as opinion leaders and patient-directed interventions, may be necessary in order to improve the care of AMI patients.

[1]  R. Hiss,et al.  Continuing education in pulmonary disease for primary-care physicians. , 2015, The American review of respiratory disease.

[2]  S B Soumerai,et al.  Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. , 1998, JAMA.

[3]  H. Krumholz,et al.  Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. , 1998, JAMA.

[4]  V. Fuster,et al.  Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1997, Circulation.

[5]  J. Gurwitz,et al.  Coronary thrombolysis for the elderly. Is clinical practice really lagging behind evidence of benefit? , 1997, JAMA.

[6]  H. Krumholz,et al.  Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. , 1997, JAMA.

[7]  J. Gurwitz,et al.  Delayed Hospital Presentation in Patients Who Have Had Acute Myocardial Infarction , 1997, Annals of Internal Medicine.

[8]  R. Collins,et al.  Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. , 1997, New England Journal of Medicine.

[9]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[10]  Richard P. Lewis,et al.  ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction , 1996 .

[11]  E. Antman,et al.  Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. , 1996, Archives of internal medicine.

[12]  D. Hosmer,et al.  The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study. , 1996, Archives of internal medicine.

[13]  A D Oxman,et al.  Changing physician performance. A systematic review of the effect of continuing medical education strategies. , 1995, JAMA.

[14]  H. Krumholz,et al.  Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. , 1995, JAMA.

[15]  U Ludwigs,et al.  Acute Physiology and Chronic Health Evaluation II scoring system in acute myocardial infarction: a prospective validation study. , 1995, Critical care medicine.

[16]  Fibrinolytictherapytrialistsf.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[17]  E. Cook,et al.  Relationship of Age with Eligibility for Thrombolytic Therapy and Mortality Among Patients with Suspected Acute Myocardial Infarction , 1994, Journal of the American Geriatrics Society.

[18]  J. Buring,et al.  The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States. , 1994, Archives of internal medicine.

[19]  J. Eisenberg,et al.  Changing physicians' practices. , 1993, Tobacco control.

[20]  P. Vokonas,et al.  Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. , 1993, Circulation.

[21]  G. Lamas,et al.  Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. , 1992, The New England journal of medicine.

[22]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.

[23]  Eugene Vayda,et al.  Opinion leaders vs audit and feedback to implement practice guidelines. Delivery after previous cesarean section. , 1991, JAMA.

[24]  J. Gurwitz,et al.  Coronary thrombolysis for the elderly? , 1991, JAMA.

[25]  S B Soumerai,et al.  Principles of educational outreach ('academic detailing') to improve clinical decision making. , 1990, JAMA.

[26]  R. Collins,et al.  Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. , 1989, Circulation.

[27]  D Draper,et al.  Interpreting hospital mortality data. The role of clinical risk adjustment. , 1988, JAMA.

[28]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[29]  S B Soumerai,et al.  Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. , 1984, The Milbank Memorial Fund quarterly. Health and society.

[30]  John B. Kidd,et al.  Judgement under Uncertainty: Heuristics and Biasses , 1983 .

[31]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[32]  G. Bole,et al.  Evaluation of a continuing education program in rheumatoid arthritis. , 1980, Arthritis and rheumatism.

[33]  E. Antman,et al.  Adherence to National Guidelines for Drug Treatment of Suspected Acute Myocardial Infarction , 1996 .

[34]  D. Hosmer,et al.  Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. , 1994, Archives of internal medicine.

[35]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[36]  D. Commerce.  Statistical abstract of the United States , 1978 .